SEARCH

SEARCH BY CITATION

References

  • 1
    Schoenfeld DA, Rosenbaum C, Horton J, Wolter J, Falkson G, DeConti RC. A comparison of adriamycin versus vincristine and adriamycin, versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50: 275762.
  • 2
    Borden EC, Amato D, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987; 5: 84050.
  • 3
    Borden EC, Amato DA, Edmondson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990; 66: 8627.
  • 4
    Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Chemother Rep 1976; 60: 199203.
  • 5
    Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7: 12631.
  • 6
    Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Freidrich C, Brennan MF. Prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion doxorubicin in patients with extremity soft tissue sarcoma, with an analysis of prognostic factors. Cancer 1991; 68: 12219.
  • 7
    Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma. Cancer 1982; 49: 122130.
  • 8
    Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 16006.
  • 9
    Subramanian S, Wiltshaw E. Chemotherapy of sarcoma. Lancet 1978; 2: 6836.
  • 10
    Buesa JM, Mouridsen HT, Santoro A, Somers R, Bramwell V, van Oosterom AT, et al. Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a Phase II trial by the European Organization for Research on Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep 1984; 68: 6834.
  • 11
    Presgrave P, Woods RL, Tattersall MH, Coates AS, Levi JA, Fox RM, et al. Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate. Cancer Treat Rep 1987; 71: 10878.
  • 12
    Karakousis CP, Rao U, Carlson M. High-dose methotrexate as secondary chemotherapy in metastatic soft-tissue sarcomas. Cancer 1980; 46: 13458.
  • 13
    Vaughn CB, McKelvey E, Balcerzak S, Loh K, Stephens R, Baker L. High-dose methotrexate with leucovorin rescue plus vincristine in advanced sarcoma: a Southwest Oncology Group study. Cancer Treat Rep 1984; 68: 40910.
  • 14
    Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988; 6: 14911500.
  • 15
    Quirt I, Eisenhauer E, Knowling M, Warr D, Bramwell V, Rusthoven J, et al. A Phase 2 study of trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1988; 7: 275.
  • 16
    Schiesel JD, Carbasi M, Magill G, Casper E, Cheng E, Marks L, et al. Oral piritrexim: a Phase II study in patients with advanced soft tissue sarcoma. Invest New Drugs 1992; 10: 9798.
  • 17
    DeGraw IT, Brown VH, Tagawa H, Kisliuk RL, Gaumont Y, Sirotnk FM. Synthesis and antitumor activity of 10-alkyl, 10-deaza-aminopterin: a convenient synthesis of 10-deaza-aminopterin. J Med Chem 1982; 251: 122730.
  • 18
    Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ. New folate analogs of the 10-deaza-aminopterin series: basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984; 12: 1825.
  • 19
    Shum KY, Kris MG, Gralla RJ, Burke MT, Marks LD, Heelan RT. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with Stage III and IV non-small-cell lung cancer. J Clin Oncol 1988; 6: 44650.
  • 20
    Li WW, Lin JT, Chang YM, Schweitzer B, Bertino JR. Prediction of antifolate efficacy in a rat sarcoma model. Int J Cancer 1991; 49: 2348.
  • 21
    Li W-W, Lin JT, Tong WP, Trippett TM, Brennan MF, Bertino JR. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992; 52: 14348.
  • 22
    Creekmore SP, Urba WJ, Longo DL. Principles of the clinical evaluation of biologic agents. In: DeVitaVTJr, HellmanS, RosenbergSA, editors. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991: 6786.
  • 23
    Miller AB, Hoogstraten B, Staquet M. Reporting the results of cancer treatment. Cancer 1981; 47: 20714.
  • 24
    Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7: 120816.
  • 25
    Loehrer PJ Sr, Sledge GW Jr, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional Phase II trial. J Clin Oncol 1989; 7: 16559.
  • 26
    Presant CA, Russell WO, Alexander RW, Fu YS. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Oncology Group experience. J Clin Oncol 1986; 4: 16581661.